Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
507.00    2.00 (0.40%)
Bid:
505.00
Ask:
507.00
Spread: 2.00 (0.396%)
Market Cap: £2.24b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

27 Jul 2017 07:00

27 July 2017 – Tate & Lyle PLC

TRADING STATEMENT

This Trading Statement covers the period from 1 April 2017 to 30 June 2017, which is the first quarter of the financial year.

The Group made an encouraging start to the year with profit in constant currency ahead of the comparative period, and volume ahead in both divisions.

In core Speciality Food Ingredients:

North America, where the overall Food and Beverage market remained soft, saw modest volume growth with firmer volume from some larger customers, and also continued to make progress in broadening its customer base. Asia Pacific and Latin America, and Europe, Middle East and Africa delivered strong volume growth.

In the remainder of the Speciality Food Ingredients division, Food Systems volume was in line with the comparative period and SPLENDA® Sucralose performed as expected.

In Bulk Ingredients, the core business performed well driven by solid demand for sweeteners and industrial starches, firm US bulk sweetener margins, and continued strong manufacturing performance. In Commodities, performance was ahead of the comparative period.

Overall, we continue to expect that the Group will make underlying progress in the full year.

END

A conference call will be held today at 07.30am BST, hosted by Javed Ahmed, Chief Executive and Nick Hampton, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666

Password: Tate & Lyle

A replay of this call will be available after the end of the live call for 14 days until 10 August 2017.

UK replay number: +44 (0) 20 8196 1998

Replay access PIN: 3389225#

For more information contact Tate & Lyle PLC:

Christopher Marsh, Group VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media Relations

Tel: +44 (0) 203 727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations at more than 30 facilities worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2017, Tate & Lyle sales totalled £2.8 billion. For more information, please visit http://www.tateandlyle.com.

SPLENDA® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170726006037/en/

Copyright Business Wire 2017

Date   Source Headline
8th Jul 20213:14 pmRNSHolding(s) in Company
1st Jul 20214:40 pmRNSBlock listing Interim Review
1st Jul 20214:38 pmRNSTotal Voting Rights
15th Jun 20212:15 pmRNSAnnual Financial Report
14th Jun 20212:05 pmRNSHolding(s) in Company
14th Jun 20212:00 pmRNSHolding(s) in Company
9th Jun 20213:49 pmRNSDirector/PDMR Shareholding
1st Jun 20212:34 pmRNSTotal Voting Rights
27th May 20217:00 amRNSFinal Results
4th May 202111:30 amRNSTotal Voting Rights
28th Apr 202110:00 amRNSDirectorate Change
26th Apr 20217:00 amRNSResponse to media speculation
13th Apr 20213:45 pmRNSHolding(s) in Company
1st Apr 202112:00 pmRNSTotal Voting Rights
25th Mar 202110:00 amRNSDirectorate Changes
23rd Mar 20213:00 pmRNSHolding(s) in Company
12th Mar 202111:00 amRNSDirector Declaration
1st Mar 202111:00 amRNSTotal Voting Rights
26th Feb 202111:00 amRNSDirector Declaration
15th Feb 20214:43 pmRNSHolding(s) in Company
15th Feb 20214:40 pmRNSHolding(s) in Company
15th Feb 20214:37 pmRNSHolding(s) in Company
10th Feb 202111:15 amRNSAcquisition
28th Jan 20217:00 amRNSTrading Statement
21st Jan 20217:00 amRNSVivid Sehgal Appointed Chief Financial Officer
12th Jan 20213:30 pmRNSDirector/PDMR Shareholding
4th Jan 20213:05 pmRNSBlock listing Interim Review
4th Jan 20213:04 pmRNSTotal Voting Rights
30th Dec 20201:00 pmRNSBoard Changes
7th Dec 202011:06 amRNSDirector/PDMR Shareholding
1st Dec 20207:00 amRNSTATE & LYLE ACQUIRES SWEET GREEN FIELDS
5th Nov 20207:00 amRNSHalf-year Report
28th Oct 20207:00 amRNSTate & Lyle to acquire tapioca business
14th Oct 202011:00 amRNSDirector Declaration
7th Oct 20207:00 amRNSDirectorate Change
2nd Oct 202011:55 amRNSDirector/PDMR Shareholding
1st Oct 20202:30 pmRNSTotal Voting Rights
17th Sep 20207:30 amRNSBlock Listing
8th Sep 202010:00 amRNSDirector/PDMR Shareholding
1st Sep 202012:00 pmRNSTotal Voting Rights
5th Aug 20204:30 pmRNSDirector/PDMR Shareholding
3rd Aug 20202:00 pmRNSTotal Voting Rights
23rd Jul 20201:00 pmRNSResult of AGM
23rd Jul 20207:00 amRNSTrading Statement
2nd Jul 20205:45 pmRNSBlock listing Interim Review
1st Jul 20203:06 pmRNSRights attaching to the listed share capital
1st Jul 20203:05 pmRNSTotal Voting Rights
9th Jun 20203:00 pmRNSAnnual Financial Report
2nd Jun 20203:56 pmRNSDirector/PDMR Shareholding
21st May 20207:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.